Genenta Science S.p.A.: Form 20-F for the period ended Dec 31, 2024
Filed with the SEC on Mar 28, 2025 and accepted by EDGAR at Mar 28, 2025, 16:25 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2024-01-01 to 2024-12-31 | EUR 4.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2024-01-01 to 2024-12-31 | −EUR 9.8m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2024-01-01 to 2024-12-31 | −EUR 8.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | −EUR 0.49 | us-gaap:EarningsPerShareDiluted |
| Diluted shares (weighted) | 12 months2024-01-01 to 2024-12-31 | 18,273,490 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −EUR 6.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | EUR 4.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-12-31 | EUR 4.0k | us-gaap:Cash |
| Current assets | At period end2024-12-31 | EUR 14.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | EUR 14.8m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | EUR 2.1m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2024-12-31 | EUR 12.5m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2024-12-31 | 18,289,866 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001641172-25-001207. Last ingested by Listed: Nov 2, 2026, 06:07 ET. Listed shows no prices and gives no investment advice.